Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pancreatic cancer: from bench to bedside.

Literature DB >> 28090514

Pancreatic cancer: from bench to bedside.

Yaokai Ma¹, Qing Wu¹, Xin Li¹, Xiaoqiang Gu¹, Jiahua Xu¹, Jinzu Yang¹.

Abstract

Pancreatic cancer is recognized as the king of carcinoma, and the gap between basic research and clinical practice is difficult to improve the treatment effect. Translational medicine builds an important bridge between pancreatic cancer basic research and clinical practice from the pathogenesis, early diagnosis of pancreatic carcinoma, drug screening, treatment strategies and metastasis prediction. This article will carry on the concrete elaboration to the above several aspects.

Entities: Disease

Keywords: Pancreatic cancer; review; translational medical research

Year: 2016 PMID： 28090514 PMCID： PMC5220038 DOI： 10.21037/atm.2016.11.57

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

29 in total

1. Adenomatous polyposis coli and translational medicine.

Authors: J Geraghty
Journal: Lancet Date: 1996-08-17 Impact factor: 79.321

2. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

Authors: Andrew D Rhim; Paul E Oberstein; Dafydd H Thomas; Emily T Mirek; Carmine F Palermo; Stephen A Sastra; Erin N Dekleva; Tyler Saunders; Claudia P Becerra; Ian W Tattersall; C Benedikt Westphalen; Jan Kitajewski; Maite G Fernandez-Barrena; Martin E Fernandez-Zapico; Christine Iacobuzio-Donahue; Kenneth P Olive; Ben Z Stanger
Journal: Cancer Cell Date: 2014-05-22 Impact factor: 31.743

3. Clinical and pathologic features of familial pancreatic cancer.

Authors: Jeremy L Humphris; Amber L Johns; Skye H Simpson; Mark J Cowley; Marina Pajic; David K Chang; Adnan M Nagrial; Venessa T Chin; Lorraine A Chantrill; Mark Pinese; R Scott Mead; Anthony J Gill; Jaswinder S Samra; James G Kench; Elizabeth A Musgrove; Katherine M Tucker; Allan D Spigelman; Nic Waddell; Sean M Grimmond; Andrew V Biankin
Journal: Cancer Date: 2014-10-14 Impact factor: 6.860

4. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Authors: Pawel K Mazur; Alexander Herner; Stephano S Mello; Matthias Wirth; Simone Hausmann; Francisco J Sánchez-Rivera; Shane M Lofgren; Timo Kuschma; Stephan A Hahn; Deepak Vangala; Marija Trajkovic-Arsic; Aayush Gupta; Irina Heid; Peter B Noël; Rickmer Braren; Mert Erkan; Jörg Kleeff; Bence Sipos; Leanne C Sayles; Mathias Heikenwalder; Elisabeth Heßmann; Volker Ellenrieder; Irene Esposito; Tyler Jacks; James E Bradner; Purvesh Khatri; E Alejandro Sweet-Cordero; Laura D Attardi; Roland M Schmid; Guenter Schneider; Julien Sage; Jens T Siveke
Journal: Nat Med Date: 2015-09-21 Impact factor: 53.440

5. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.

Authors: V Bhattacharjee; Y Zhou; T J Yen
Journal: Cell Cycle Date: 2014 Impact factor: 4.534

6. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.

Authors: Neus Martínez-Bosch; Maite G Fernández-Barrena; Mireia Moreno; Elena Ortiz-Zapater; Jessica Munné-Collado; Mar Iglesias; Sabine André; Hans-Joachim Gabius; Rosa F Hwang; Françoise Poirier; Carolina Navas; Carmen Guerra; Martin E Fernández-Zapico; Pilar Navarro
Journal: Cancer Res Date: 2014-05-08 Impact factor: 12.701

7. Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines.

Authors: Heng-Hsiung Wu; Wendy W Hwang-Verslues; Wen-Hsin Lee; Chun-Kai Huang; Pei-Chi Wei; Chia-Lin Chen; Jin-Yuh Shew; Eva Y-H P Lee; Yung-Ming Jeng; Yu-Wen Tien; Che Ma; Wen-Hwa Lee
Journal: J Exp Med Date: 2015-03-02 Impact factor: 14.307

8. Targeting mTOR dependency in pancreatic cancer.

Authors: Douglas C Morran; Jianmin Wu; Nigel B Jamieson; Agata Mrowinska; Gabriela Kalna; Saadia A Karim; Amy Y M Au; Christopher J Scarlett; David K Chang; Malgorzata Z Pajak; Karin A Oien; Colin J McKay; C Ross Carter; Gerry Gillen; Sue Champion; Sally L Pimlott; Kurt I Anderson; T R Jeffry Evans; Sean M Grimmond; Andrew V Biankin; Owen J Sansom; Jennifer P Morton
Journal: Gut Date: 2014-04-09 Impact factor: 23.059

9. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes.

Authors: Ang Li; Jennifer P Morton; YaFeng Ma; Saadia A Karim; Yan Zhou; William J Faller; Emma F Woodham; Hayley T Morris; Richard P Stevenson; Amelie Juin; Nigel B Jamieson; Colin J MacKay; C Ross Carter; Hing Y Leung; Shigeko Yamashiro; Karen Blyth; Owen J Sansom; Laura M Machesky
Journal: Gastroenterology Date: 2014-01-23 Impact factor: 22.682

10. Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition.

Authors: Ramadevi Subramani; Elizabeth Gonzalez; Arunkumar Arumugam; Sushmita Nandy; Viviana Gonzalez; Joshua Medel; Fernando Camacho; Andrew Ortega; Sandrine Bonkoungou; Mahesh Narayan; Alok kumar Dwivedi; Rajkumar Lakshmanaswamy
Journal: Sci Rep Date: 2016-01-25 Impact factor: 4.379

5 in total

1. Hydroxyeicosatetraenoic acids in patients with pancreatic cancer: a preliminary report.

Authors: Tomasz Bodnarczuk; Anna Deskur; Katarzyna Dolegowska; Barbara Dolegowska; Teresa Starzynska; Wojciech Blogowski
Journal: Am J Cancer Res Date: 2018-09-01 Impact factor: 6.166

2. Jumonji AT-rich interactive domain 1B promotes the growth of pancreatic tumors via the phosphatase and tensin homolog/protein kinase B signaling pathway.

Authors: Xudong Shen; Guilian Cheng; Liming Xu; Wei Wu; Zhengrong Chen; Peng Du
Journal: Oncol Lett Date: 2018-05-02 Impact factor: 2.967